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Purpose: To retrospectively evaluate and compare the loco-regional progression free survival (PFS), 
overall survival (OS) and acute effects of the two breast palliative regimes used in patients with locally 
advanced or metastatic breast cancer between 2010 and 2013 in a single institution.  
Methods: Compliance to treatment, acute skin reactions, progression free and overall survival were 
retrospectively evaluated in patients who received palliative breast radiotherapy for locally advanced 
breast cancer between 2010 and 2013. The radiotherapy regimes were either 4Gy per fraction for 5 
fractions treated 4 times a week (20Gy) or 6Gy per fraction for 6 fractions treated once a week (36Gy). 
They may have received previous chemotherapy with minimal or no clinical response, as well as 
hormonal treatment.  
Results: Forty three patients were followed up over a median period of 24 months, 14 of which 
received 20Gy and 29 received 36Gy. The average age was 64 years old. Compliance was 88% in both 
groups. Both groups had either grade 1 (71% vs 62%), grade 2 (21% vs 24%) or grade 3 (8% vs 14%) 
acute skin reactions. No grade 4 skin reactions were documented. The PFS was shorter at 4.5 months in 
the 20Gy group compared to 7.7 months in the 36Gy group (p=0.27). The OS was also shorter at 25.8 
months in the 20Gy group compared to 29.6 months in the 36Gy group (p=0.51) 
Conclusion: This study did not show a statistically significant difference in terms of PFS and OS between 
the two radiotherapy regimes. They both remain reasonable options in local palliation in patients with 
locally advanced breast cancer. 
Key Words: Locally advanced breast cancer, palliative radiotherapy, radiation regimes 
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MMED STUDY PROTOCOL 
Background 
Breast cancer is one of the leading types of cancer in women, in both the developing and 
developed countries. In countries with established screening programs, the majority of breast 
cancers are detected at an early stage. However, in countries, especially developing countries, 
where the screening programs are not as well established and access to medical care is not as 
efficient, many patients present with more advanced disease. Due to lack of adequate cancer 
registries in the developing countries, we are unable to accurately state what percentage of patients 
present with advanced disease. 
The treatment of locally advanced breast cancer and metastatic breast cancer remain an oncologic 
challenge. Different institutions across the world have different protocols according to their 
resources. 
According to the ESO-ESMO guidelines1, the treatment of locally advanced disease involves 
multiple modalities. The aim is to downstage the tumour using neo-adjuvant chemotherapy or 
using hormonal treatment where appropriate, followed by surgery and adjuvant radiotherapy and 
biological agents. For metastatic disease, there is a lack of evidence on how to locally palliate the 
disease. 
The issue that we face at our facility, and in many developing countries, is that we have limited 
access to modern chemotherapy regimes and no access to the required biological agents in the state 
sector. Therefore, if patients do not respond to the chemotherapy and/or the hormonal treatment, 
palliative radiotherapy remains the only option to treat complications of locally advanced disease 
(such as ulceration or bleeding). We also have a sub-set of patients with a good ECOG 
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performance status (see appendix c), but with metastatic disease. Due to the nature of their 
metastatic disease, they are expected to have a life expectancy of at least 6 months (for example 
those with bone metastases). There is no consensus as to how to treat these groups of patients. 
The intent for patients with advanced disease is palliation, but, as the majority of patients have a 
significant lifespan of at least 6 months, we would aim to give them as good a quality of life as 
possible. 
Previously the palliative radiotherapy regime of 20Gy in 5 fractions was used at Groote Schuur 
Hospital, as well as at the other facilities in South Africa. 
Since 2012, Groote Schuur Hospital introduced the 36Gy regime, where the patient has one 6 Gy 
fraction per week for 6 weeks. The rationale behind using this regime is based on radiobiological 
studies, which have shown that the alpha/beta ratio of breast cancer is similar to those of late 
responding tissues. Fractionation sensitivity is quantified in terms of the linear quadratic equation. 
If cell survival is plotted on a graph, the point where the alpha component (non repairable damage) 
is equal to the beta component (repairable damage) is the alpha/beta ratio. Studies have shown that 
late responding tissues have lower alpha/beta ratios than early responding tissues. They are 
therefore more sensitive to dose per fraction.2 Breast cancers respond to radiotherapy similarly to 
late responding tissues, therefore, they are more sensitive to dose per fraction. This is at the risk of 
more late effects, but as these patients are for palliative intent, they may not live long enough for 
those long terms effects to manifest. 
Studies in elderly patients with breast cancer who could not cope with longer course of 
radiotherapy, have shown equivalent rates of loco-regional control using the hypo-fractionated 
regime compared to the normofractionated regime. The patients were given radiotherapy once a 
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week for 5 or 6 weeks at a dose of between 6Gy- 6.5 Gy.3,4,5  This regimen has been suggested for 
frail patients with fungating tumours.6
The clinical outcomes of these two palliative regimes have not been established nor compared. It is 
therefore the aim of this study to retrospectively review the outcomes of these two regimes. 
Study aims and objectives: 
Research question 
 WE propose to assess treatment outcomes of the breast radiotherapy regime used at Groote Schuur 
Hospital from 2010 to 2011 compared to the regime used from 2012 to 2013 for locally advanced 
or metastatic breast cancer. 
Study Aim 
To retrospectively compare the treatment outcomes of the 20Gy in 5 fractions (4 fractions per 
week) regime used from 2010 to 2011 to the 36Gy in 6 fractions (1 fraction per week) regime used 




To compare the treatment outcomes of the two regimes, specifically looking at: 
• Overall survival
• Acute effects of radiotherapy
• Loco regional progression free survival
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Secondary Objectives: 
• Determining percentage of patients presenting with advanced disease.
• Determining demographics of patients presenting with advanced disease.
Study population: 
Inclusion criteria: 
• Patients 18 years and older
• Registered with the Combined Breast Clinic at Groote Schuur Hospital between 2010 and
2013.
• They should have proven and documented evidence of locally advanced or metastatic
breast cancer.
• Patients should have either been treated with the palliative regime of either 20.00Gy or
36.00Gy during the above time periods.
• They may have had previous chemotherapy with minimal or no clinical response.
• Patients who are oestrogen receptor and/or progesterone receptor positive on hormonal
treatment may be included.
Exclusion criteria: 
• Chest wall irradiation post mastectomy or breast irradiation post lumpectomy.
Scientific Design: 
Methods and Materials: 
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The patients diagnosed with locally advanced or metastatic breast cancer between 2010 and 2013, 
were identified using the Groote Schuur Hospital Department of Radiation Oncology Electronic 
Patient Registry. The Electronic Patient Registry is registered with the Human Research Ethics 
Committee (approval number R016/2013.Their hospital and Radiotherapy folders will be 
retrospectively reviewed and the relevant data extracted. 
The relevant data required, is the age of the patient, stage of disease (see appendix 1), HIV status, 
previous chemotherapy, ER or PR positivity, grading of skin reactions while on radiotherapy (see 
appendix 2) and time interval to local progression and death. There would be approximately 50 
patients in total in the study group. 
A univariate analysis will be done to assess the influence these factors have on the overall response 
and loco regional recurrence free survival. 
The information will be obtained by noting the patients’ disease status at each follow up visit to the 
Breast Clinic at Groote Schuur Hospital. 
As these are palliative patients with disseminated disease, it will be noted in patients who have 
demised, whether the cause was due to distant disease or lack of local response to radiotherapy. 
Date of Audit: 
The folders to be reviewed will be those who presented with locally advanced or metastatic breast 
cancer and received either 20.00Gy or 36.00Gy radiotherapy to the breast, from 2010 to 2013 at 
Groote Schuur Hospital. 
Data Collection: 
The data will be collected from the GSH radiotherapy and hospital folders. It will then be recorded 
into customized data sheets and then transferred onto an Excel spreadsheet. 
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Statistical analysis: 
Statistical analysis of the data will be performed, using GraphPad prism version 6 for Windows. 
Survival curves will be generated using the Kaplan-Meier method and compared using the log rank 
test. A p-value of <0.05 will considered as statistically significant. Categorical variables will be 
calculated using the Fisher test or the Chi-Square test.  
 Access to records 
The routine clinical records will be assessed using the electronic patient registry of the Radiation 
Oncology Department at Groote Schuur Hospital.  
As this is a retrospective audit, only the patient folders will be used for data collection. There will 
be no patient contact. 
Ethical considerations: 
Risk and Benefits 
This is a retrospective audit; therefore there is minimal risk to the patients. All patients will be de-
identified. 
The benefit of this audit, is that we will be able to compare two breast radiotherapy regimes and 
assess clinical outcomes of the two palliative regimes.  
Informed consent 
This is a retrospective study using the patients’ folders only. As there is no patient contact, we 
would request a waiver of informed consent. All patients will be de-identified during data 
collection and analysis.  
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Privacy and confidentiality 
Confidentiality and privacy will be maintained by de-identifying patient data, using passwords on 
electronic documents, etc. 
 
Resources 
For the literature review, Pubmed, Google and available journal articles will be used. 
No other resources will be used, besides the patient data available on the Groote Schuur Hospital 
Department of Radiation Oncology patient registry and in patient folders. 
 
What happens at the end of the study? 
The data results will be documented in a publication style format and will be submitted to the 














Treatment regime 1: Total dose:20.00Gy @ 4.00Gy per fraction in 5 fractions. Four fractions per 
week. (2010-2011) 
Treatment regime 2: Total dose 36.00Gy @ 6.00Gy per fraction in 6 fractions. One fraction per 
week. (2012-2013) 
Overall survival: the time from diagnosis to last follow-up or demise due to any cause. Time to 
Loco regional recurrence: time from start of treatment to first documented local progression of 
disease or death. 
Locally advanced breast cancer:  
• Tumours which involve the skin of the breast or underlying muscles of the chest 
• Involve multiple local lymph nodes (axillary, supraclavicular, infraclavicular) 
• Inflammatory breast cancer 
Metastatic breast cancer 













1. Cordosa F, Costa A, Nortan l, et al ESO-ESMO 2nd International Consensus Guidelines for
Advanced Breast Cancer (ABC2) The Breast 2014 (http:dx.doi.org/10.1016/j.breast) & Annals of 
Oncology (Ann Oncol 2014;25: http/dx.doi.org/10.1093/annoc/mdu385) 
2. Hall EJ, Amato JG Radiobiology for the Radiologist 7th edition 2012, Chapter 19 and 23.
3. Maher M, Campana F, Mosseri V, et al Breast Cancer in elderly women: A retrospective
analysis of combination treatment with Tamoxifen and once weekly radiation. International 
Journal of Radiation Oncol Bio Phys 1995,31:783-789 
4. Ortholan C, Hannoun-Levi JM, Ferrero JM, et al Long term results of adjuvant hypofractionated
radiotherapy for breast cancer in elderly patients. International Journal of Radiation Oncol Bio 
Phys 2005; 61:154-162 
5. Kirova YM, Campana F, Savignoni A, et al Breast Conserving treatment in elderly: long term
results of adjuvant hypofractionated and normofractionated radiotherapy. International Journal of 
Radiation Oncol Bio Phys 2009; 75: 76-81 
6.Barrett A, Dobbs J, Morris S, Roques T Practical Radiotherapy Planning 4th Edition 2009
Chapter 22: 280 
15	




Objectives of literature review  
The objectives of this literature review are to provide the reader with a background of the 
management of locally advanced and metastatic breast cancer and the current, international 
treatment guidelines recommended in developed countries. It also provides the reader with insight 
into the history of hypofractionation in breast cancer. 
Literature Search strategy  
For this study, articles relating to locally advanced and metastatic breast cancer were searched 
using the following search engines: Google Scholar, Google, Pubmed, Text books and journal 
articles. The main search terms were: locally advanced breast cancer, metastatic breast cancer, 
once weekly hypo-fractioned radiotherapy in breast cancer and palliative radiotherapy in breast 
cancer.  Only publications in English were considered. 
The majority of the data published on metastatic and locally advanced breast cancer  are from 
developed countries, where there has been a shift towards treating patients with improved 
chemotherapy regimes and targeted agents. There were a few studies using the hypo-fractionated 
once weekly regime in the elderly population, but these were patients with radical treatment intent. 
These are  retrospective studies and no meta-analyses or Phase III trials were found in the 
databases. There are currently no studies using the hypo-fractionated once weekly regime in the 
palliative setting.  
Interpretation of literature  
In order to understand and discuss the results of the current study, a detailed review of the 
available literature was performed and discussed.  
The review summarized the available literature as follows: 
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Background and epidemiology 
Breast cancer is the most frequently diagnosed cancer (23% of total cancer cases) and the leading 
cause of death (14% of deaths), in females, worldwide.1 According to the Globocan 2008 
estimates, approximately 1.37 million women are diagnosed with breast cancer per year. In 
economically developing countries, it’s the leading cause of cancer related deaths amongst women. 
According to Vorobiof et al, the incidence of breast cancer in South Africa was approximately 
16.6% in 2001.2 At that time, 70% of the patients presenting with breast cancer were white, Asian 
or mixed race and 30% were black.  But, majority of the black patients presented with stage 3 and 
4 disease. In higher income countries, such as the USA, the breast cancer mortality incidence has 
been decreasing by approximately 2% per year since 1990 with only about 15% of patients 
presenting with advanced stage disease.3 This may be attributed to the earlier detection of breast 
cancer by the implementation of awareness and screening programs, easier access to diagnostic 
testing and timeous implementation of effective treatment. In contrast, in low to middle income 
countries, approximately 60-80% of the patients present at more advanced stages.4 Due to lack of 
adequate cancer registries in the developing countries, we are unable to accurately state what 
percentage of patients present with more advanced disease. The advanced presentation, as well as 
poorer access to care and limited treatment options, results in higher breast cancer mortality 
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incidences. However, research at Groote Schuur Hospital, revealed that there may be other factors 
at play in developing countries, which may affect cancer survival.3 Factors such as patients’ 
distrust of “western medicine” and the use of traditional medicine first, lack of understanding of 
the disease and allowing older, often conservative, family members to make treatment decisions 
are commonplace. There are also the financial implications, as patients cannot afford to lose 
working hours to come for investigations, chemotherapy and daily for radiotherapy. 
Worldwide, the treatment of locally advanced breast cancer and metastatic breast cancer is an 
oncologic challenge. In developing countries, this is confounded by the situations mentioned 
previously. Protocols for the treatment of advanced breast cancer differ amongst institutions, based 
on the resources available to that country. In the Western Cape, despite the fact that we have the 
advantage of  expert multidisciplinary teams, there is  limited access to many of the chemotherapy 
agents and no access to the targeted agents used in advanced breast cancer. The rest of the South 
African state sector as well as other developing countries mirror this.3,4 In fact, other developing 
countries especially in Africa, are significantly limited with regard to oncology care and 
resources.5-7 
Definition of Locally Advanced Breast Cancer (LABC) and Metastatic Breast Cancer (MBC) 
Advanced breast cancer comprises of locally advanced breast cancer (LABC) and metastatic breast 
cancer (MBC).8 The definition of locally advanced breast cancer is non metastatic disease, with 
any tumour more than 5cm in diameter or that involves the skin or chest, as well as the presence of 
fixed axillary lymph nodes or ipsilateral supraclavicular, infraclavicular and internal mammary 
nodes. It also includes a more homogenous form of LABC called inflammatory breast cancer 
(IBC).8,9According to the American Joint Committee on Cancer (AJCC) staging system, it includes 
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all Stage 3 disease and well as Stage 2b disease.10 Metastatic breast disease (AJCC Stage 4) is the 
presence of distant metastasis, with or without locally advanced disease. 
Treatment Guidelines: Overview 
According to the European Society of Medical Oncology (ESMO) guidelines, the treatment of 
locally advanced disease involves multiple modalities, ideally, under the guidance of a multi 
disciplinary team.8 The aim is to downstage the tumour using neo-adjuvant chemotherapy and 
hormonal treatment (if the patient is oestrogen receptor (ER)/ progesterone receptor (PR) positive), 
followed by surgery, adjuvant radiotherapy and biological agents. The choice of first line treatment 
for LABC depends on disease related and patient related factors.  
In patients who are Triple Negative (HER-2-Neu, ER and PR negative), Anthracycline and 
Taxane-based chemotherapy is recommended.  
In approximately 33% of locally advanced and metastatic breast cancers and 40% of inflammatory 
breast cancers, there is amplification or overexpression of the human epidermal growth factor 
receptor-2 (HER-2). It’s a trans membrane receptor tyrosine kinase, which is associated with more 
aggressive disease and poorer outcomes.  If the patient is HER-2-Neu positive, anti-HER-2 therapy 
is recommended since it increases the rate of pathological complete response.3,11 The addition of 
Trastuzumab (anti-HER-2 monoclonal antibody) neo-adjuvantly and adjuvantly significantly 
improves 3 year event-free survival (71% vs 56% without Trastuzumab).12 Patients with ER or PR 
positive LABC, may also benefit from Anthracycline and Taxane based treatment, as well as from 
endocrine therapy. The decision whether to use endocrine therapy or chemotherapy as initial 
treatment, depends on the tumour grade and biomarker expression, as well as the patients’ 
menopausal status, comorbidities, performance status and personal preferences.  
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For patients who responded adequately to neo-adjuvant chemotherapy, local therapy is followed by 
surgery. This entails a radical mastectomy and axillary node clearance in majority of cases. If there 
has been a significant response to chemotherapy, breast conservation surgery may be considered. 
Subsequently, all patients will have loco-regional postoperative radiotherapy to the chest wall and 
loco-regional nodes.  
Treatment Guidelines MBC: Overview 
Metastatic breast cancer (MBC) is incurable, but still treatable, especially if there are limited 
metastases. The intent of treatment is palliative, providing symptomatic relief and optimization of 
the length and quality of life. Median survival is approximately 18 to 24 months in these patients, 
though in some circumstances, for example with bone metastasis, the life expectancy may be 
longer. If the patient has a good performance status and has locally advanced disease as well, local 
palliation could optimize their quality and length of life.13 There are, however, limited randomized 
studies in these groups of patients. 
Treatment Guidelines MBC: Systemic treatment 
The systemic treatment of MBC includes endocrine therapy, chemotherapy and targeted biological 
agents. The choice of treatment depends on disease related factors such as hormone status, HER2 
status, tumour burden and need for rapid disease control; as well as patient related factors such as 
biological age, menopausal status, co-morbidities, performance status, socio-economic and 
psychological factors, patient preference and therapies available.3,13 
If patients are ER/PR positive, without extensive or symptomatic visceral involvement, endocrine 
therapy is the first choice of treatment. Types of endocrine therapies available are: selective 
oestrogen receptor modulators (Tamoxifen), oestrogen receptor down regulators (Fulvestrant), 
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luteinising hormone-releasing hormone analogues (Goserelin), third generation aromatase 
inhibitors (Anastrozole, Letrozole, Exemestane), Progestins and anabolic steroids. Patients on 
long-term endocrine therapy may develop resistance14,15 Clinical studies have shown that 
mammalian target of rapamycin (mTOR) inhibitors enhances the efficacy of endocrine therapy.16,17 
If patients are HER2 positive, the addition of Trastuzumab to endocrine treatment has shown to 
improve progression free survival.18 Lapatinib is a second anti Her2 agent. Trials have looked at 
using Lapatinib in combination with Capecitabine in patients who progressed on Herceptin, 
Anthracyclines and Taxanes. It showed a progression free survival of 8.4 months versus 4.4 
months in the placebo arm.19 Studies have also considered combining Lapatinib with Trastuzumab, 
if the patient progresses on Trastuzumab alone.20  
If patients are ER positive with symptomatic or extensive visceral metastasis, ER negative or have 
progressed on hormonal treatment, chemotherapy is the treatment of choice.13 Chemotherapy 
agents that may be used include Anthracyclines, Taxanes, Vinca Alkaloids, Capecitabine, 5-
Fluorouricil, Methotrexate, Platinum agents, Mitomycin C and Gemcitabine. If the patient is HER2 
positive, the chemotherapy may be used with the targeted agents as mentioned previously. Other 
targeted agents available are Pertuzumab, Palbociclib and Ado- Trastuzumab Emantasine (T-
DM1).  
Radiotherapy: Overview 
The challenge that we face at our facility, and in many developing countries, is the limited access 
to modern chemotherapy regimes and almost no access to the required biological agents in the 
state sector. Therefore, patients who do not respond to the chemotherapy and/or the hormonal 
treatment, palliative radiotherapy is the only option to treat complications of locally advanced 
disease (such as ulceration of breast and bleeding). There are a group of patients, often triple 
negative or hormone receptor negative patients, with a relatively good ECOG performance status, 
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but with limited metastatic disease. Those who are hormone receptor negative, are treated with 
systemic therapy. In the public sector the options include Anthracycline based chemotherapy, 
Taxane based chemotherapy (on a named patient basis), Navelbine and Capecitabine. Those who 
are hormone receptor positive are treated initially with hormonal treatment. There is no access to 
targeted biological agents in the state sector due to cost restrictions. If a patient’s disease 
progresses on the hormonal treatment, as well as on chemotherapy or are unfit for chemotherapy, 
palliative local radiotherapy is the remaining option available for local control. As mentioned 
previously, if they have limited metastatic disease, they are expected to have a life expectancy of at 
least 6 months. Radiotherapy plays an important role in local palliation by reducing risk of further 
haemorrhage, ulceration and malignant brachial plexopathy, thereby improving their quality of 
life, as well as potentially increasing their life span.3,21 
Current radiotherapy regimes 
There are various palliative breast radiotherapy regimes prescribed for local control of disease. 
Institutions in South Africa use a variety of regimes: a single fraction of 8Gray (Gy), fractioned 
treatment of 20Gy at 4Gy per fraction for 5 fractions or 30Gy at 3Gy per fraction for 10 
fractions.22 The treatment plan depends on the resources available at the facility, patient ECOG 
performance status and disease factors. Since 2012, Groote Schuur Hospital has been prescribing a 
hypo-fractionated 36Gy regime, where the patient has one 6Gy fraction per week for 6 weeks to a 
total of 36Gy.  
In the 1960’s a limited number of studies were performed examining hypofractionation in the 
palliative setting. These trials were, however, abandoned due to poor technique, poor radiation 
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quality and subsequent severe late effects.23,24 A review of literature failed to find any recent 
studies investigating the optimal radiotherapy dose and fractionation for local breast palliation. 
 
There are studies and retrospective reviews that have been published using the once weekly hypo-
fractionated radiotherapy regime. It was, however, investigated in the elderly population as 
definitive radiotherapy25,26 or as adjuvant treatment post mastectomy.27,28 Breast cancer is known 
to increase in incidence as women age.27 With increasing age, other factors such as medical factors 
(stage of disease, performance status, co-morbidities) as well as socio-economic factors need to 
taken into consideration when deciding on the appropriate treatment approach. The elderly, often, 
cannot attend multiple sessions of radiotherapy per week for a few weeks and may present with 
more advanced disease. For these reasons, elderly patients are, sometimes, unable to receive 
adequate multimodality treatment.  This was the rationale behind the studies done using a hypo-
fractionated radiotherapy regime in the elderly as it afforded the patients therapeutic advantages 
without being too cumbersome on the patient physically, socially and financially.27 These trials 
looked at the incidence of acute and late side effects of hypo-fractionated radiotherapy, tolerance 
and compliance to radiotherapy, the local control rate, disease free survival, cause specific survival 
and overall survival.  
 
Radiobiology 
The rationale behind using this specific radiotherapy regime is based on radiobiological studies, 
which have shown that the alpha/beta ratio of breast tissue is similar to those of late responding 
tissues. Fractionation sensitivity is quantified in terms of the linear quadratic equation, which 
describes the relationship between fractionation size and tissue response.29 If cell survival is 
plotted on a graph, the point where the alpha component (non-repairable damage) is equal to the 
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beta component (repairable damage) is the alpha/beta ratio. Studies have shown that late 
responding tissues have lower alpha/beta ratios than early responding tissues. They are therefore 
more sensitive to dose per fraction. Numerous studies have proven that squamous carcinomas of 
the head and neck region, cervix and bronchus are less sensitive to the size of the fraction 
compared to the late-responding tissue. Therefore, if they are hypo-fractionated (i.e. >2Gy per 
fraction), the probability of tumour cure is less and with more normal tissue complications than if 
they were given 2Gy per fraction in the same overall treatment time.30 Data has suggested that 
primary breast adenocarcinomas are more sensitive to fraction size compared to the squamous 
carcinomas and therefore respond to radiotherapy similarly to dose limiting normal tissues such as 
skin, subcutaneous tissues, muscle and ribs.30 
Evidence for Hypofraction in Breast Cancer 
A randomized clinical trial was undertaken in 1986, with the aim  to test the hypothesis that hypo-
fractionation is as effective as the standard 2Gy per fraction and offered reduced cost to patients 
and the health facilities.31 The primary endpoint was the late effect of healthy tissue and secondary 
endpoints were tumour recurrence and palpable fibrosis. This trial generated reliable estimates for 
α/β for late change in breast (3.6Gy) and late change in breast appearance (3.1Gy). It did not 
generate reliable estimates for α/β for tumour control. This trial was used as a basis for the UK 
Standardisation of Radiotherapy Trail (START trial).32 These α/β ratios were confirmed by a 
similar randomized phase three trial in 200531. The START A Trial studied women with early 
breast cancer who received adjuvant radiotherapy post breast conserving surgery or mastectomy.32 
The patients were either randomized to 50Gy in 25 fractions or 41.6Gy in 13 fractions or 39Gy in 
13 fractions. Treatment duration in all three arms was 5 weeks. The data was consistent with the 
hypothesis that breast cancer and dose limiting normal tissue respond similarly to change in 
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radiotherapy fraction size. The adjusted estimates of the α/β ratio for tumour control was 4.6Gy 
and for late change in breast appearance was 3.4Gy.32 The START B trial ran concurrently with 
the START A trial. It compared 40Gy in 15 fractions of 2.67Gy per fraction in 3 weeks to the 
control group of 50Gy in 25 fractions 2Gy in 5 weeks. The results were consistent with the 
START A trial that hypo-fractionation, over a reduced treatment time (accelerated therapy), 
produced the same rate of loco-regional relapse and late adverse effects as the standard 50Gy 
treatment. The hypofractionated regimes tested in the START trials are now standard practice in 
most institutions. The risk of hypofractionation is the effects on the late responding tissue. The 
larger the fraction, the greater the expected late effect will be. Results of studies on the long-term 
side effects of hypofractionated radiotherapy for breast cancer show comparable results for the risk 
of local recurrence and cosmetic outcome.33,34 
 
Evidence for once weekly radiotherapy 
In 1987, Rostom et al, investigated using once weekly hypofractionated radiotherapy (6.5Gy 
weekly for 6 fractions) as definitive or adjuvant treatment in elderly patients. Of the 84 
participants, 18 had undergone a mastectomy. This study demonstrated that the hypofractionated 
regime was well tolerated. There were less acute side effects than conventional radiotherapy 
(50Gy) and only 1 of the 66 patients who had an intact breast developed late fibrosis of the 
breast.35 
Maher et al published a retrospective review, evaluating ER positive elderly women who were 
unfit for surgery or normofractionated radiotherapy, in 1995.25 The patients had received 
Tamoxifen 20mg daily, as well as once weekly radiotherapy of 6.5Gy for 5 fractions to the 
involved breast and 2 fractions to the tumour bed. The majority of the patients were stage 1 and 2. 
This study showed that at 36 months, the overall survival was 87%, the disease specific survival 
26	
was 88% and the local control rate was 86%. Ten percent of the patients had WHO grade 2 skin 
reactions and 3% had WHO grade 3 skin reactions. There was late fibrosis of the breast in 39% of 
the patients, but late tissue damage was accepted as adverse sequelae in the patients. No 
pneumonitis or rib fractures were reported. These patients were however treated in the lateral 
decubitus position, which would reduce dose to lung and ribs.  
 Courdi et al performed a similar study in 2006 with the same dose fractionation.26 A third of these 
patients had T3 and T4 tumours. Their local control rate was similar at 85%. They had grade 1 and 
grade 2 skin reactions in 20% and 9% of the patients respectively. No grade 3 skin reactions were 
reported. There was late fibrosis in the breast of 49% of the patients, majority being grade 1 and 
grade 2. The progression free survival at 5 years was 78%. 
In 2005, Orthalan et al studied the same hypofractionated regime at the same institution as 
Courdi.27 They, however, reviewed those patients who received the radiotherapy in the post-
operative setting. Seventy six percent of the patients received adjuvant hormones as well. More 
than 85% of the patients tolerated the treatment. The outcomes showed a 5- and 10- year disease 
free survival of 80% and 71.5% respectively and an overall survival of 71.6% and 46.5%. The 
local relapse rate was 2.3%. WHO grade 1 and 2 skin effects were seen in 26% of patients, with no 
grade 3 effects. Late effects was comparable to those seen in patients receiving 42.5Gy in 16 
fractions.33 
Kirova et al compared adjuvant hypo-fractionated radiotherapy to normofractionated radiotherapy 
in the post-operative setting.28 Patients either received 50Gy in 25 fractions or 6.5Gy once weekly 
for five fractions. The outcomes were very similar to the above trial, except that there was a higher 
rate of late effects (33%) in the hypofractionated regimen. Thus also affirming that once-weekly 




Patients with advanced disease, particularly in developing countries, may display a similar 
combination of disease and social characteristics. Control of local disease could improve quality 
and length of life, especially if no distant metastasis or limited metastasis is present. Based on the 
studies in the elderly population, using the once weekly regimen is an acceptable regimen to use in 
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ABSTRACT 
Purpose: To retrospectively evaluate and compare the loco-regional progression free survival (PFS), 
overall survival (OS) and acute effects of the two breast palliative regimes used in patients with locally 
advanced or metastatic breast cancer between 2010 and 2013 in a single institution.  
 
Methods: Compliance to treatment, acute skin reactions, progression free and overall survival were 
retrospectively evaluated in patients who received palliative breast radiotherapy for locally advanced 
breast cancer between 2010 and 2013. The radiotherapy regimes were either 4Gy per fraction for 5 
fractions treated 4 times a week (20Gy) or 6Gy per fraction for 6 fractions treated once a week (36Gy). 
They may have received previous chemotherapy with minimal or no clinical response, as well as 
hormonal treatment.  
 
Results: Forty three patients were followed up over a median period of 24 months, 14 of which 
received 20Gy and 29 received 36Gy. The average age was 64 years old. Compliance was  88% in both 
groups. Both groups had either grade 1 (71% vs 62%) , grade 2 (21% vs 24%) or grade 3 (8% vs 14%) 
acute skin reactions. No grade 4 skin reactions were documented. The PFS was shorter at 4.5 months in 
the 20Gy group compared to 7.7 months in the 36Gy group (p=0.27). The OS was also shorter at 25.8 
months in the 20Gy group compared to 29.6 months in the 36Gy group (p=0.51) 
 
Conclusion: This study did not show a statistically significant difference in terms of PFS and OS between 
the two radiotherapy regimes. They both remain reasonable options in local palliation in patients with 
locally advanced breast cancer. 
 
Key Words: Locally advanced breast cancer, palliative radiotherapy, radiation regimes 
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Introduction 
Breast cancer is the most frequently diagnosed cancer and the leading cause of death in women 
worldwide.1 According to Vorobiof et al, in 2001, the incidence of breast cancer in South Africa was 
approximately 16.6% with a fair percentage of the patients presenting with advanced disease2. Despite 
great strides in the treatment of breast cancer, the management of locally advanced breast cancer 
remains an oncologic challenge. This is especially true in developing countries where health resources 
and access to care are not readily available to the general population. 4,7 
According to the European Society of Medical Oncology guidelines, the treatment of locally advanced 
breast cancer involves multiple modalities.8 The aim of treatment is to downstage the tumour utilising 
neo-adjuvant chemotherapy or hormonal treatment where appropriate  followed by surgery, adjuvant 
radiotherapy and biological agents. If patients present with distant metastases, the aim of multimodality 
treatment is local control, as well as improvement in quality and length of life without the treatment 
being too taxing on the patient physically, socially and financially. 
 
Our institution boasts an expert, multidisciplinary team, but we have limited access to certain 
chemotherapy agents and no access to the biological targeted agents used in advanced breast cancer 
treatment. This lack of treatment agents is mirrored in other South African state hospitals and in 
developing countries as well.3,7 In fact, in many of the developing countries especially in Africa, the 
institutions are significantly limited with regard to oncology care and resources.5 
In patients who do not respond to chemotherapy and/or hormonal treatment, palliative radiotherapy is 
the remaining option in the treatment of complications of locally advanced disease such as ulceration  
bleeding of the breast primary. There are various palliative breast radiotherapy regimes prescribed for 
local control of disease.22 
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Institutions in South Africa use a variety of regimens: a single fraction of 8 Gray (Gy), fractioned 
treatment of 20Gy at 4Gy per fraction for five fractions or 30Gy at 3Gy per fraction for 10 fractions.22 
The treatment plan depends on the resources available at the facility, patient Eastern Collaborative 
Oncology Group (ECOG) performance status and disease factors.  
Since 2012, our institution adopted a hypofractionated 36Gy regime, where the patient has a single 6Gy 
fraction per week for six weeks to a total of 36Gy. This regime has been studied in the elderly 
population who required adjuvant radiotherapy after breast conserving surgery for early breast 
cancer27,28 and elderly patients who were unfit for surgery but eligible for hormonal treatment.25,26 
Studies indicate that elderly patients tended to present with more advanced disease, have multiple co-
morbidities and poorer performance status, rely more on social support, have poor access to 
transportation to hospital and have more financially constraints.27,36 This was the rationale behind the 
studies done using a hypofractionated radiotherapy regime in the elderly as it afforded the patients 
therapeutic advantages without it being too cumbersome on the patient physically, socially and 
financially.27 
 Patients with advanced disease, particularly in developing countries, may display a similar 
combination of disease and social characteristics.3 This is the rationale behind investigating this regime 
for locally advanced breast cancer in our institution. The aim of this study is to retrospectively evaluate 
the outcomes of the 20Gy and 36Gy fractionation regimes, Specific primary objectives were overall 
survival, acute effects of radiotherapy and loco regional progression free survival. The secondary 
objective was to determine the demographics of patients presenting with advanced disease.  
 
METHODS AND MATERIALS 
Patients 
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This is a retrospective cohort analysis. Patients, treated between 2010 and 2013, with palliative 
radiotherapy to whole breast for locally advanced breast cancer (with or without distant metastasis), 
were identified using the Groote Schuur Hospital Department of Radiation Oncology Electronic Patient 
Registry.  
The inclusion criteria were patients 18 years and older, registered with the Combined Breast Clinic at 
Groote Schuur Hospital, with proven and documented evidence of inoperable locally advanced breast 
cancer. Patients were treated with either a total dose of 20Gy or 36Gy to the involved whole breast. 
Patients on hormonal treatment, if they were oestrogen or progesterone receptor (ER/PR) positive, were 
also included as well as those who received prior chemotherapy. Patients were excluded if they 
received chest wall irradiation post mastectomy or breast irradiation post lumpectomy. Department 
clinical notes were used to obtain the relevant data. 
Variables included age, stage at presentation, ER/PR status, hormonal and chemotherapy received, 




Between 2010 and 2011, the standard palliative regimen used for patients with relatively good 
performance status, was a total of 20Gy to whole breast (4Gy weekly for five fractions). The equivalent 
dose in 2Gy per fraction (EQD2) was 26.67Gy, using an α/β of four for late effects.30,31 Since 2012, an 
alternative palliative regimen was introduced. Patients received a total of 36Gy to the whole breast (one 
fraction weekly for six weeks). The EQD2 was 60Gy, once again using an α/β of four for late effects. 
The time factor was not taken into account. 
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In both regimens, the patients were marked up on the simulator. They were positioned supine on a 
breast board, angled at 7.5 degrees. The patients were treated with Cobolt60 γ-rays and no bolus was 
used on the skin.  
The local skin effects were documented according to the Radiation Therapy Oncology Group (RTOG) 
Skin Toxicity Guidelines. Overall survival was defined as the time from registration at the Combined 
Breast Clinic at GSH to death or end of follow-up period. The progression free survival was defined as 
the time from the start of radiotherapy to the first sign of loco-regional progression or death. 
Statistical Analysis 
Statistical analysis of data was performed using Stata (version 13). The differences between the two 
treatment groups were analysed using t-tests for continuous variables and chi-square analysis for 
categorical variables. Survival curves for overall survival (OS) and progression free survival (PFS) 
were generated using Kaplan Meier method. The statistical significance of differences in survival 
between the two regimes was determined by the log-rank test. A p-value of <0.05 was considered 
statistically significant for all variables. 
Results 
The median follow up was 25 months (range 3.1 to 83.2 months). Overall, there were 43 patients who 
received radiotherapy, with palliative intent, to their whole breast. Fourteen patients received a total 
dose of 20Gy (regimen 1) and 29 patients received a total dose of 36Gy (regimen 2).  
Demographics 
Patient demographic information is presented in table 1. The median age was 66 years (range, 36-78 
years) in the 20Gy group versus 63 years (range 36-86 years) in the 36Gy group (p=0.28). The disease 
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stage at presentation was not statistically significant between the two groups. In the 20Gy group, 64% 
(vs 66% in regimen 2) of the patients presented with inoperable, locally advanced disease (Stage 3) and 
36% (vs 34% in 36Gy group) presented with locally advanced disease, as well as distant metastasis 
























































Additional treatment (concurrent, adjuvant or neoadjuvant) 
Table 2 represents additional treatment received by patients. In terms of hormonal treatment, 13% of 
the 20Gy group was treated with Tamoxifen alone and 87% received Tamoxifen and an aromatase 
inhibitor during the course of their disease. In the 36Gy group 22% were treated with Tamoxifen alone, 
17% were treated with an aromatase inhibitor and 61% received both Tamoxifen and aromatase 
inhibitor. There was no significant difference in hormonal therapy received between the two study 
groups. However, the data indicates a trend towards a significant difference between the two groups 
with regards to a trial of chemotherapy before radiotherapy. In the 20Gy group 71% received 







20Gy	 36Gy	 Total	 p-value	
	
	
n	=	14		 n	=	29		 n	=	43		 	
Hormonal	therapy	
	















Chemotherapy	 71%	 41%	 51%	 0.06	
 
Radiotherapy 
Results of radiotherapy received are presented in Table 3.  The radiotherapy was well tolerated in both 
groups, with 88% of patients completing their course of radiotherapy. Of the patients who received 
20Gy, 93% completed the course versus 86% who received 36Gy. Of the five patients who did not 
complete radiotherapy, one (in 36Gy group) died before completion of treatment. The other four 
patients defaulted treatment for unknown reasons. The median equivalent dose received was 26.40Gy 
and 59.20Gy by the 20Gy and 36Gy regimes respectively. 
	
Table3:	Radiotherapy	received	
Radiotherapy Regimen 1 (20Gy in 5 
fractions) 
 






EQD2 mean dose (range)  26.4Gy  




Completion of  RT 
n (%) 







In the 20Gy group, 71% had RTOG Grade 1 acute skin effects, 21% had Grade 2 effects, and 8% had 
Grade 3 effects (Table 4). Similarly, in the 36Gy group, 62% had grade 1 effects, 24% had Grade 2 
























There was a statistically significant difference in survival between the two groups. In the 20Gy group 
92% of the patients had died at the end of the follow up period compared to 58% in the 36Gy group 
(p=0.045; CI 0.12-0.94). The cohort follow up period was 25 months (range 3.1 to 83.2 months).  
The median overall survival (OS) was 29.1 months (range 19.35 to 44.81 months) for the cohort. The 
median OS in the 20Gy group was 25.8 months (range 11.56 - 43.03 months) and 29.6 months (range 







The overall median progression free survival (PFS) was 5.1 months (range 3.44 -10.61). In the 20Gy 
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A univariate analysis of the patient demographics, with regard to its influence on survival, showed that 
ER status was a statistically significant prognostic factor (p=0.01). In the 20Gy group, 71% (n=10) of 
the patients died due to progression of local disease, two patients due to visceral metastasis and one 
patient died secondary to brain metastasis. Conversely, in the 36Gy group, only 14% (n=4) died due to 
local progression, nine patients due to distant  metastasis,  and four patients due to medical co-
morbidities.  
Of the 14 patients that progressed locally, 80% was Stage 3 in the 20Gy group (compared to 75% in the 
36Gy group) and 20% Stage 4 (compared to 25% in the 36Gy group) (p=0.837). The median age in the 
20Gy group was 60 years and in the 36Gy group was 73 years (p=0.08; CI 56.28-71.5). In the 20Gy 
group 60% were ER negative compared to 50% in the 36Gy group (p=0.733). The differences between 
the two groups were not statistically significant, the exception being with regards to chemotherapy 
treatment. In the 20Gy group, 80% received chemotherapy, compared to 0% in the 36Gy group 
(p=0.006). A multivariate analysis could not be performed, as the sample size was too small. 
	
Discussion 
This was a small, single institution, retrospective study of two palliative breast hypofractionation 
radiotherapy regimens, used for locally advanced breast cancer between 2010 and 2013.  
 
In the 1960’s a limited number of studies were performed examining hypo-fractionation in the 
palliative setting. These trials were, however, abandoned due to poor technique, radiation quality and 
subsequent severe late effects.23,24 A review of the literature failed to find any recent studies 
investigating the optimal radiotherapy dose and fractionation for local breast palliation.  
There are studies and retrospective reviews that have been published using the once weekly 
hypofractionated radiotherapy regime. It was, however, investigated in the elderly population as 
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definitive radiotherapy or as adjuvant treatment post mastectomy. These trials looked at the incidence 
of acute and late side effects of hypofractionated radiotherapy, tolerance and compliance to 
radiotherapy, the local control rate, disease free survival, cause specific survival and overall survival. 
 
In 1987, Rostom et al, investigated once weekly hypofractionated radiotherapy (6.5Gy weekly for 6 
fractions) as definitive or adjuvant treatment in elderly patients.37 Of the 84 participants, 18 had 
undergone a mastectomy. This study showed that the hypofractionated regime was well tolerated. 
Maher et al, published a retrospective review of elderly patients who received once weekly adjuvant 
radiotherapy (6.5Gy weekly for 6 to seven fractions) and Tamoxifen in 1994.25 The majority of the 
patients were stage 1 and 2. This study also showed that the regime was well tolerated by 87% of the 
patients. In our study the weekly hypofractionated regime was also well tolerated with 88% of patients 
completing treatment. 
In the study by Rostom et al, there were less acute side effects than conventional radiotherapy (50Gy) 
and only 1 of the 66 who had an intact breast had late fibrosis of the breast.37 
Ten percent of the patients in the study by Maher et al, had grade 2 skin reactions and 3% grade 3 
reactions.25 There was late fibrosis of the breast in 39% of the patients. No pneumonitis or rib fractures 
were reported. These patients were, however, treated in the lateral decubitus positions, which would 
reduce dose to lung and ribs. In our study, the acute skin reactions in the 36Gy group were higher, with 
62%, 24% and 14% having Grade 1, grade 2 and grade 3 skin reactions, respectively. However, the 
previous study groups were majority T1 and T2 breast tumours, whereas our study group was only T3 
and T4 tumours.  
In 2006, Courdi et al performed a study with definitive RT at the same dose fractionation as the Maher 
trial.26 This study is comparable to our cohort as a third of these patients had T3 and T4 tumours. 
However, they had grade 1 and grade 2 skin reactions in 20% and 9% of the patients respectively. No 
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grade 3 skin reactions were reported. There was late fibrosis in the breast of 49% of the patients, 
majority being grade 1 and grade 2. As it is difficult to assess skin reaction when the skin is red, 
ulcerated and inflamed, the presence of T3 and T4 tumours in the our study may have resulted in over-
reporting of skin toxicity  
The main concern with hypofractionation is the increased incidence of late effects, with fibrosis 
occurring in 39% of patients according to the studies done in elderly. 27,28 Of note, Kirova et al 
compared normofractionated radiotherapy to hypo-fractionated radiotherapy in the postoperative 
setting. Results were similar between the two groups, except that there was a higher rate of late effects 
(33%) in the hypofractionated regimen.28 However, due to the palliative intent of our treatment, the late 
complication risk was accepted. Skin necrosis and rib fractures were not reported in patient folders but 
this non-reporting may be due to patients not surviving a long period of time in which to experience 
late effects. This is in keeping with previously reported trials.25,26 
The local progression free survival (PFS) was not statistically significant between the two groups. This 
may be due to the study being underpowered. The 36Gy group received a higher equivalent dose 
compared to the 20Gy group. Therefore it was hypothesised that they would have a better PFS. The 
results found that ER status was a significant prognostic factor. This could be due to the added benefit 
of hormonal treatment in local control. Previous studies have also found that ER status; nodal status 
and tumour size were independent prognostic factors. 25,27 This PFS cannot be compared to the 
previous studies, as most of the patients in the previous trials were either early stage cancers or treated 
adjuvantly with radiotherapy.25,37 
 Similarly, the overall survival was also not statistically significant between the two groups. It cannot 
be compared to other studies as these patients are being treated with palliative intent. 
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There were a number of limitations in this study. Firstly, the cohort reported on was small. Secondly, 
since the study was retrospective, patient records were heavily relied upon. However, these records did 
not adequately document patient and treatment characteristics such as performance status, quality of 
life, early and late effects of radiotherapy and cosmesis. In addition, skin reactions were not graded 
according to the RTOG skin toxicity guidelines, making grading susceptible to observer bias. It should 
be noted that T3 and T4 patients are difficult to grade due to the presence of ulceration and bleeding, 
secondary to disease. As mentioned previously, late effects were not well recorded, but it was not of 
great concern as these were palliative patients with limited life span and the benefit of local control 
outweighed the risk of late effects due to higher overall dose. 
In conclusion, the 36Gy regime may be a reasonable alternative for local control to the 20Gy regime in 
patients with locally advanced breast cancer. There is no statistically significant difference between the 
two regimens in term of overall survival, progression free survival and acute skin effects. Previous 
trials have shown promising results using a once weekly hypo-fractionated regime in the curative 
setting. Trials however need to be performed in the palliative setting to assess its clinical effectiveness 
in terms of local control and to assess its impact on the quality of life of the patients compared to daily 
doses. 
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A: TNM CLINICAL CLASSIFICATION (AJCC 7th edition, 2010)
Primary tumour (T): 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: Carcinoma in situ; intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the 
nipple with no associated tumour. Note: Paget's disease associated with a tumour is classified 
according to the size of the tumour.  
T1: Tumour 2.0 cm or less in greatest dimension T1mic: Micro invasion 0.1 cm or less in greatest 
dimension T1a: Tumour more than 0.1 but not more than 0.5 cm in greatest dimension T1b: 
Tumour more than 0.5 cm but not more than 1.0 cm in greatest dimension T1c: Tumour more than 
1.0 cm but not more than 2.0 cm in greatest dimension  
T2: Tumour more than 2.0 cm but not more than 5.0 cm in greatest dimension T3: Tumour more 
than 5.0 cm in greatest dimension  
T4: Tumour of any size with direct extension to (a) chest wall or (b) skin, only as described 
below. Note: Chest wall includes ribs, intercostal muscles, and serratus anterior muscle but not 
pectoral muscle.  
T4a: Extension to chest wall T4b: Oedema (including peau d'orange) or ulceration of the skin of 
the breast or satellite skin nodules confined to the same breast T4c: Both of the above (T4a and 
T4b) T4d: Inflammatory carcinoma*  
Regional lymph nodes (N):  
NX: Regional lymph nodes cannot be assessed (e.g., previously removed)  
N0: No regional lymph node metastasis  
N1: Metastasis to movable ipsilateral axillary lymph node(s)  
N2: Metastasis to ipsilateral axillary lymph node(s) fixed to each other or to other structures 
N3: Metastasis to ipsilateral internal mammary lymph node(s)  
Distant metastasis (M):  
MX: Presence of distant metastasis cannot be assessed 
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M0: No distant metastasis  
M1: Distant metastasis present (includes metastasis to contralateral supraclavicular lymph nodes) 
AJCC Staging  
Stage 0 Tis, N0, M0   
Stage I T1, N0, M0 (T1 includes T1mic)  
Stage IIA T0, N1, M0/ T1, N1, M0 /T2, N0, M0   
Stage IIB T2, N1, M0/ T3, N0, M0  
Stage IIIA T0, N2, M0 /T1, N2, M0 /T2, N2, M0 /T3, N1, M0  
Stage IIIB T4, Any N, M0  
Stage IIIC Any T, N3, M0   




B:  RTOG guidelines: ACUTE RADIATION DERMATITIS 
 











• Tender/bright erythema 
• Patchy moist 
desquamation 
• Moderate oedema 
• Confluent/moist 
desquamation other 
than skin folds 
• Pitting oedema 
• Ulceration 
• Haemorrhage 




















C: ECOG performance status 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature 
2 Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours. 
3 Capable of only limited self-care, confined to bed or chair more than 50% of 
waking hours 
4 Completely disabled. Cannot carry on self-care. Totally confined to bed or chair. 
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I. Data Capture Instrument
1. DATA SHEET
1. Folder number
2. Age: 1)<35 2)35-55 3)56-69 4)>69 
3. Stage: 1) iii 2)iv
4. Date of diagnosis
5. ECOG Performance status at diagnosis: 1 2 3 4 
6. Palliative Regime: 1)1 2)2
7. Date of start of treatment
8. Date of progression
9. Date of death
10. Cause of death: 1) local 2)distant metastasis 3) other
11. Date last seen:
12. ECOG performance status at last visit: 1 2 3 4 
13. Estrogen receptor/progesterone receptor: 1) positive 2)negative
14. Hormonal treatment: 1)Tamoxifen 2)Aromatase Inhibitor 3)Both
15. Chemotherapy: 1)yes 2)no
16. Skin reaction during RT: 1)Grade 1  2)Grade 2 3)Grade 3 4)Grade 4
17. Completion of radiotherapy: 1) yes 2)no
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